Skip to main content

Table 2 Patient, intervention and outcome characteristics of the studies

From: Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature

   Patient characteristics Intervention characteristics  
S.No Study Criteria for TNFi withdrawal Duration of RA during TNFi withdrawal, years DAS28 during withdrawal TNFi DMARDs Duration of dosage, months Post-withdrawal follow-up time, months DAS28 for/at Relapse Events Total Number Event%
1 Quinn et al., 2005 [32] 0.5 I M 10.6 12 3 10 30
2 Nawata et al., 2008 [33] DAS28-ESR < 2.6 after 24 weeks of TNFi therapy 2.4 6.6 I C; M 6 to 12 14.2 5 9 55.55 (If follow-up is 12 months)
3 Brocq et al., 2009 [34] DAS28 < 2.6 after TNFi therapy for 6 months 11.3 5.54 I, 5%; A, 25%; E, 75% M, L 40.25 12 > 3.2 15 20 75
4 Tanaka et al., 2010 [35] DAS28 < 3.2 during > 24 weeks; Prednisolone therapy < 5 mg/day 5.9 5.5 I M, P 12 > 3.2 46 102 45.1
5 van den Broek et al., 2013 [36] DAS44 < 2.4 for 6 months 1.9 1.3 I 11 12 > 2.4* 50 108 48
6 van der Maas et al., 2012 [37] DAS28 > 2.6 after TNFi therapy for 6 months 12 I M, CS 67 12 > 1.2 of baseline 20 51 39
7 Harigai et al., 2012 [38] DAS28-CRP < 2.7 10.3 1.6 A M, CS 45.8 12 DAS28-CRP > 2.7 15 22 68.18
8 Hirata et al., 2013 [39] DAS28-ESR < 2.6 after 6 months 7.1 A M 6 21 50 42
9 Smolen et al., 2013 [40] DAS28 < 3.2 at 36 months of treatment 6.9 E M 36 12 > 3.2 113 197 57.36
10 Iwamoto et al., 2014 [41] DAS28 < 2.6 8.2 1.9 (MEDIAN) I M, CS 6 > 3.2 16 40 40 (initial 42; 2 dropouts)
11 Kádár et al., 2014 [42] Discontinuation for reasons including remission, low disease activity, or infections 15 3.8 Not mentioned specifically 20 15 5 33 15.16
12 Tanaka et al., 2015 [43] DAS28-ESR < 2.6 for > 6 months, steroid free 15 3.8 A M 20 12 DAS28-ESR > 2.6 27 52 51.92
13 Moghadam et al., 2016 [44] DAS28 < 3.2 during last 6 months; TNFi therapy ≥1 yr. 12 1.98 A, 51%; E, 40%; I, 5%; G, 3%; C, 1% M, 82%; M + G, 4%; G, 1%; O, 7%; NONE, 6% 12 > 3.2 plus an increase of ≥0.6 over baseline 272 531 51.2
14 NCT00808509 (ADMIRE) 10.4 1.98 A M 12 13 15 87
15 NCT00858780 (DOSERA) E M 11 2 12 16.66 (Etanercept 50 mg)
16 NCT00858780 (DOSERA) b E M 11 1 12 8.33 (Etanercept 25 mg)
  1. TNFi tumour necrosis factor inhibitor, RA rheumatoid arthritis, DMARD conventional synthetic disease-modifying antirheumatic drugs, DAS28 disease activity score of 28 joints, CRP C-reactive protein, ESR erythrocyte sedimentation rate, A Adalimumab, E Etanercept, I Infliximab, G Golimumab, C Certolizumab, M Methotrixate, G Glucocorticoids, C Corticosteroid, L Leflunomide, P Prednisolone, O other; * = DAS 44